|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Spark_Therapeutics
gptkb:Tibotec_Pharmaceuticals
focused on biotech
|
|
gptkbp:annual_report
|
published yearly
|
|
gptkbp:benefits
|
comprehensive packages
|
|
gptkbp:capital
|
over 200 billion CHF
|
|
gptkbp:ceo
|
gptkb:Severin_Schwan
|
|
gptkbp:clinical_trial
|
collaborative efforts
extensive database
over 1,000 ongoing
|
|
gptkbp:collaborations
|
with global partners
|
|
gptkbp:community_engagement
|
local initiatives
|
|
gptkbp:community_health
|
supporting access to medicines
|
|
gptkbp:community_support
|
healthcare initiatives
|
|
gptkbp:conducts_research_on
|
gptkb:Levi_Garraway
|
|
gptkbp:digital_transformation
|
investing in technology
|
|
gptkbp:employees
|
over 100,000
|
|
gptkbp:financial_performance
|
consistent growth
|
|
gptkbp:founded
|
gptkb:1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:governance
|
high standards
|
|
gptkbp:head_of_diagnostics
|
gptkb:Thomas_Schinecker
|
|
gptkbp:head_of_state
|
gptkb:Bill_Anderson
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche, Switzerland
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:innovation
|
leading in personalized medicine
|
|
gptkbp:innovation_hubs
|
established worldwide
|
|
gptkbp:invention
|
thousands of patents
|
|
gptkbp:investment
|
in R& D
|
|
gptkbp:investment_strategy
|
strong growth
|
|
gptkbp:leadership
|
diverse team
in diagnostics
|
|
gptkbp:market_share
|
significant in oncology
|
|
gptkbp:marketing_strategy
|
patient-centric approach
|
|
gptkbp:partnerships
|
gptkb:Astra_Zeneca
gptkb:Foundation_Medicine
gptkb:Illumina
gptkb:Novartis
academic institutions
|
|
gptkbp:philanthropy
|
gptkb:Roche_Foundation
|
|
gptkbp:products
|
biopharmaceuticals
diagnostics
|
|
gptkbp:provides_guidance_on
|
influential in healthcare
|
|
gptkbp:regulatory_compliance
|
multiple products
|
|
gptkbp:research_areas
|
multiple indications
|
|
gptkbp:research_focus
|
oncology
central nervous system
infectious diseases
immunology
|
|
gptkbp:revenue
|
over 60 billion CHF
|
|
gptkbp:social_responsibility
|
active engagement
|
|
gptkbp:stock_exchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:strategic_goals
|
long-term growth
|
|
gptkbp:subsidiaries
|
gptkb:Genentech
gptkb:Roche_Diagnostics
|
|
gptkbp:supply_chain
|
global network
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion
access to healthcare
environmental responsibility
|
|
gptkbp:training
|
continuous development
|
|
gptkbp:uses_technology
|
leader in the field
|
|
gptkbp:bfsParent
|
gptkb:Roche_Diagnostics_Research_Center
|
|
gptkbp:bfsLayer
|
5
|